Last reviewed · How we verify
Generex Oral-lyn™
Oral-lyn is an oral insulin formulation that delivers insulin through the buccal mucosa to lower blood glucose in diabetes patients.
Oral-lyn is an oral insulin formulation that delivers insulin through the buccal mucosa to lower blood glucose in diabetes patients. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Generex Oral-lyn™ |
|---|---|
| Also known as | buccal Insulin spray |
| Sponsor | Generex Biotechnology Corp. |
| Drug class | Insulin (oral formulation) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Oral-lyn uses Generex's proprietary RapidMist technology to aerosolize insulin for absorption through the oral mucosa (inside the mouth), bypassing the gastrointestinal tract where insulin would be degraded. This allows for non-invasive insulin delivery with rapid onset of action similar to injected insulin.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Oral/buccal irritation
- Cough
- Throat irritation
Key clinical trials
- Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
- Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generex Oral-lyn™ CI brief — competitive landscape report
- Generex Oral-lyn™ updates RSS · CI watch RSS
- Generex Biotechnology Corp. portfolio CI